Pfizer
NEWS
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
Technology has had a massive impact on basically every area of life. One very important part of medical research that technology has been having a noticeable impact on is clinical trials.
One-year scheme under ATAA & TADAMON initiatives for financially challenged patients
Pfizer announced its succession plan for when Ian Read steps down as chief executive officer on January 1, 2019. The new chief executive officer will be Albert Bourla, who is currently the company’s chief operating officer.
Here’s a look at who shook things up in the world of pharma and biotech this week.
The U.S. Food and Drug Administration approved Pfizer’s once-per-day oral medication Vizimpro, a first-line treatment for patients with a rare form of lung cancer, the company announced late Thursday.
The past few days has had a flurry of activity in the industry with leadership changes. Let’s take a look at some of those!
Merck and Co., like many large corporations, has a mandatory retirement age of 65 for its chief executive officer. Today the company announced its board of directors and rescinded the policy to allow its current chief executive officer, Kenneth C. Frazier, stay on beyond his 65th birthday in December 2019.
JOBS
IN THE PRESS